Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
A phase 1/2 trial of CRC01, Fludarabine, Cyclophosphamide in diffuse large b-cell lymphoma and follicular lymphoma, run by Curocell Inc., now recruiting.
Overview
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients is a phase 1/2 interventional study registered as NCT04836507 by Curocell Inc., with 91 participants planned, started 2021-03-02 and due to reach its primary completion in 2030-08-15. Interventions recorded: CRC01, Fludarabine, Cyclophosphamide. Conditions listed: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialRelmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Shares Fludarabine, Cyclophosphamide, Follicular lymphoma.
- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide.